VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before
Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound Vancouver, British Columbia - January 5, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted
Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate Vancouver, Canada and London, UK - October 11, 2009 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory
Aquinox Pharmaceuticals Inc. Names Board Member Vancouver, British Columbia - July 10, 2008 Aquinox Pharmaceuticals is pleased to announce the addition of Dr. Daniel Levitt as an independent member of the Board of Directors. Dr. Levitt joined Cerimon Pharmaceuticals Inc.
